JP2008526996A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008526996A5 JP2008526996A5 JP2007551428A JP2007551428A JP2008526996A5 JP 2008526996 A5 JP2008526996 A5 JP 2008526996A5 JP 2007551428 A JP2007551428 A JP 2007551428A JP 2007551428 A JP2007551428 A JP 2007551428A JP 2008526996 A5 JP2008526996 A5 JP 2008526996A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- group
- alkyl
- alkynyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 38
- 125000000623 heterocyclic group Chemical group 0.000 claims description 36
- 229910052739 hydrogen Inorganic materials 0.000 claims description 29
- 239000001257 hydrogen Substances 0.000 claims description 29
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 26
- 125000003118 aryl group Chemical group 0.000 claims description 25
- 125000003342 alkenyl group Chemical group 0.000 claims description 20
- 125000000304 alkynyl group Chemical group 0.000 claims description 20
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- 125000004429 atom Chemical group 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 125000003107 substituted aryl group Chemical group 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 23
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 11
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims 10
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 230000001404 mediated effect Effects 0.000 claims 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 8
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 claims 3
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 claims 3
- 101000716070 Homo sapiens C-C chemokine receptor type 9 Proteins 0.000 claims 3
- 125000006585 (C6-C10) arylene group Chemical group 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 206010063725 Idiopathic pneumonia syndrome Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 230000001760 anti-analgesic effect Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 208000007915 ichthyosis prematurity syndrome Diseases 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 4
- 241000257303 Hymenoptera Species 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64410305P | 2005-01-14 | 2005-01-14 | |
| US60/644,103 | 2005-01-14 | ||
| US74282105P | 2005-12-06 | 2005-12-06 | |
| US60/742,821 | 2005-12-06 | ||
| US75098505P | 2005-12-16 | 2005-12-16 | |
| US60/750,985 | 2005-12-16 | ||
| PCT/US2006/001341 WO2006076644A2 (en) | 2005-01-14 | 2006-01-13 | Heteroaryl sulfonamides and ccr2 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008526996A JP2008526996A (ja) | 2008-07-24 |
| JP2008526996A5 true JP2008526996A5 (cg-RX-API-DMAC10.html) | 2012-05-17 |
| JP5253815B2 JP5253815B2 (ja) | 2013-07-31 |
Family
ID=36678244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007551428A Expired - Lifetime JP5253815B2 (ja) | 2005-01-14 | 2006-01-13 | ヘテロアリールスルホンアミドおよびｃｃｒ２ |
Country Status (13)
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ536504A (en) | 2002-05-24 | 2008-04-30 | Millennium Pharm Inc | CCR9 inhibitors and methods of use thereof |
| DE60314175T2 (de) | 2002-11-18 | 2008-01-24 | Chemocentryx Inc., Mountain View | Arylsulfonamide |
| EP1748989A2 (en) * | 2004-05-12 | 2007-02-07 | ChemoCentryx Inc | Aryl sulfonamides |
| US7622583B2 (en) * | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
| ATE524182T1 (de) * | 2005-04-21 | 2011-09-15 | Merck Serono Sa | 2,3-substituierte pyrazinsulfonamide als crth2- hemmer |
| GB0524786D0 (en) * | 2005-12-05 | 2006-01-11 | Glaxo Group Ltd | Compounds |
| GB0526445D0 (en) * | 2005-12-23 | 2006-02-08 | Novartis Ag | Organic compounds |
| US20100234364A1 (en) * | 2006-07-14 | 2010-09-16 | Arindrajit Basak | Ccr2 inhibitors and methods of use thereof |
| US7718683B2 (en) | 2006-07-14 | 2010-05-18 | Chemocentryx, Inc. | Triazolyl phenyl benzenesulfonamides |
| US8519135B2 (en) * | 2006-07-14 | 2013-08-27 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2/CCR9 |
| CN101511800B (zh) * | 2006-07-14 | 2013-02-27 | 坎莫森特里克斯公司 | 三唑基苯基苯磺酰胺 |
| US20080076120A1 (en) * | 2006-09-14 | 2008-03-27 | Millennium Pharmaceuticals, Inc. | Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders |
| CA2677096A1 (en) * | 2007-01-31 | 2008-08-07 | Vertex Pharmaceuticals Incorporated | Kinase inhibitors |
| US7776877B2 (en) * | 2007-06-22 | 2010-08-17 | Chemocentryx, Inc. | N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides |
| CN101820881B (zh) | 2007-07-12 | 2013-05-01 | 坎莫森特里克斯公司 | 作为ccr2调节剂用于治疗炎症的稠合杂芳基吡啶基和苯基苯磺酰胺 |
| CA2720613A1 (en) * | 2008-04-09 | 2009-10-15 | Boehringer Ingelheim International Gmbh | 2-sulfonylamino-4-heteroaryl butyramide antagonists of ccr10 |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| CU24099B1 (es) | 2009-01-12 | 2015-06-30 | Pfizer Ltd | Derivados de sulfonamida para el tratamiento del dolor |
| JP5872552B2 (ja) | 2010-07-09 | 2016-03-01 | ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ | 化学化合物 |
| CN103201270B (zh) * | 2010-08-03 | 2015-06-24 | 日本化学医药株式会社 | P2x4受体拮抗剂 |
| CA2822039C (en) * | 2010-12-16 | 2019-05-28 | Allergan, Inc. | Sulfur derivatives as chemokine receptor modulators |
| JP6030568B2 (ja) * | 2010-12-16 | 2016-11-24 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | ケモカイン受容体調節因子としての新規１，２−ビス−スルホンアミド誘導体 |
| WO2013060865A1 (en) | 2011-10-28 | 2013-05-02 | Galderma Research & Development | New leukocyte infiltrate markers for rosacea and uses thereof |
| MX2014013499A (es) * | 2012-05-08 | 2015-11-13 | Anvyl Llc | Moduladores alostericos de receptor alfa 7 nicotinico de acetilcolina, sus derivados y usos de los mismos. |
| ES2735360T3 (es) * | 2013-12-02 | 2019-12-18 | Chemocentryx Inc | Compuestos CCR6 |
| US10421756B2 (en) | 2015-07-06 | 2019-09-24 | Rodin Therapeutics, Inc. | Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase |
| HRP20211864T1 (hr) | 2015-07-06 | 2022-03-04 | Alkermes, Inc. | Inhibitori hetero-halo histonske deacetilaze |
| ES2966111T3 (es) | 2016-06-03 | 2024-04-18 | Chemocentryx Inc | Pirrolo-piridinas y pirrolo-pirimidinas para su uso en el tratamiento de la fibrosis hepática |
| US10251888B2 (en) | 2016-06-13 | 2019-04-09 | Chemocentryx, Inc. | Method of treating pancreatic cancer |
| US10195188B2 (en) | 2016-06-13 | 2019-02-05 | Chemocentryx, Inc. | Method of treating pancreatic cancer |
| ES3015086T3 (en) | 2016-11-23 | 2025-04-29 | Chemocentryx Inc | Ccr2 inhibitors for use in treating renal diseases |
| WO2018122746A1 (en) | 2016-12-28 | 2018-07-05 | Minoryx Therapeutics S.L. | Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase |
| CN106854177B (zh) * | 2017-01-04 | 2019-10-11 | 苏州健雄职业技术学院 | 一种6-氯-4-羟基吡啶-3-甲醛的制备方法 |
| HRP20220223T1 (hr) | 2017-01-11 | 2022-04-29 | Alkermes, Inc. | Biciklički inhibitori histon deacetilaze |
| PL3664802T3 (pl) | 2017-08-07 | 2022-07-11 | Alkermes, Inc. | Bicykliczne inhibitory deacetylaz histonowych |
| EP3694504A4 (en) | 2017-10-11 | 2021-07-14 | ChemoCentryx, Inc. | TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH CRC2 ANTAGONISTS |
| WO2021007386A1 (en) | 2019-07-10 | 2021-01-14 | Chemocentryx, Inc. | Indanes as pd-l1 inhibitors |
| BR112022006018A2 (pt) | 2019-10-16 | 2022-07-12 | Chemocentryx Inc | Heteroaril-bifenil amidas para o tratamento de doenças relacionadas à pd-l1 |
| PH12022550877A1 (en) | 2019-10-16 | 2023-03-27 | Chemocentryx Inc | Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases |
| TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Ａｌｋ﹘５抑制劑和彼之用途 |
| CN113248427B (zh) * | 2021-06-01 | 2023-05-02 | 苏州大学 | 磺酰胺基烟酸衍生物、酰胺基烟酸衍生物及其制备方法和应用 |
| WO2023031308A1 (en) * | 2021-08-31 | 2023-03-09 | Artica Therapeutics B.V. | Ccr2 inhibitors |
| NL2037411B1 (en) * | 2024-04-08 | 2025-10-31 | Univ Leiden | Protac compounds |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3901855A (en) * | 1974-08-07 | 1975-08-26 | Us Air Force | Preparation of polybenzimidazoles |
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US4403607A (en) * | 1980-05-09 | 1983-09-13 | The Regents Of The University Of California | Compatible internal bone fixation plate |
| JPS61113060A (ja) * | 1984-11-08 | 1986-05-30 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料 |
| ATE167473T1 (de) * | 1990-08-20 | 1998-07-15 | Eisai Co Ltd | Sulfonamid-derivate |
| JPH06135934A (ja) * | 1991-12-27 | 1994-05-17 | Ishihara Sangyo Kaisha Ltd | ピリジン誘導体又はその塩を含有するホスホリパーゼ▲ａ２▼阻害剤、抗炎症剤又は抗膵炎剤 |
| US5514555A (en) | 1993-03-12 | 1996-05-07 | Center For Blood Research, Inc. | Assays and therapeutic methods based on lymphocyte chemoattractants |
| US5571775A (en) * | 1994-07-11 | 1996-11-05 | Dowelanco | N-aryl[1,2,4]triazolo[1,5-a]pyridine-2-sulfonamide herbicides |
| EP0896533B1 (en) * | 1996-02-22 | 2003-09-10 | Tularik, Inc. | Pentafluorobenzenesulfonamides and analogs |
| US5780488A (en) * | 1996-04-03 | 1998-07-14 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| AR015104A1 (es) * | 1996-11-13 | 2001-04-18 | Dowelanco | Compuestos de n-arilsulfilimina sustituidos, utiles como catalizadores en la preparacion de compuestos de n-arilarilsulfonamida; proceso para preparar dichos compuestos y su uso para catalizar dicha preparacion. |
| GB9803228D0 (en) * | 1998-02-17 | 1998-04-08 | Zeneca Ltd | Chemical compounds |
| EP0937711A1 (de) * | 1998-02-18 | 1999-08-25 | Roche Diagnostics GmbH | Neue Thiobenzamide, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel |
| JP4327915B2 (ja) * | 1998-03-30 | 2009-09-09 | 株式会社デ・ウエスタン・セラピテクス研究所 | スルフォンアミド誘導体 |
| US6380206B1 (en) * | 1998-11-23 | 2002-04-30 | Cell Pathways, Inc. | Method of inhibiting neoplastic cells with 4,5-diaminopyrimidine derivatives |
| JP2000159665A (ja) * | 1998-11-27 | 2000-06-13 | Nippon Kayaku Co Ltd | リウマチの予防または治療剤 |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| EP1418175A1 (en) * | 1999-06-28 | 2004-05-12 | Janssen Pharmaceutica N.V. | Respiratory syncytial virus replication inhibitors |
| JP2001089412A (ja) * | 1999-09-22 | 2001-04-03 | Otsuka Pharmaceut Co Ltd | ベンゼン誘導体またはその医薬的に許容される塩 |
| WO2001060369A1 (en) * | 2000-02-18 | 2001-08-23 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| JP2001335714A (ja) * | 2000-03-22 | 2001-12-04 | Fuji Photo Film Co Ltd | アゾ色素、その製造方法、インクジェット用インク、インクジェット記録方法 |
| US6525051B2 (en) * | 2000-03-27 | 2003-02-25 | Schering Aktiengesellschaft | N-heterocyclic derivatives as NOS inhibitors |
| JP2002036052A (ja) * | 2000-07-25 | 2002-02-05 | Sankyo Mfg Co Ltd | 自動工具交換装置 |
| US7468253B2 (en) | 2001-06-07 | 2008-12-23 | Chemocentryx, Inc. | Method for multiple chemokine receptor screening for antagonists using RAM assay |
| US7282338B2 (en) | 2001-06-07 | 2007-10-16 | Chemocentryx, Inc. | Cell migration assay |
| EP1453516A2 (de) * | 2001-10-17 | 2004-09-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren |
| US7410972B2 (en) * | 2001-12-18 | 2008-08-12 | Astrazeneca Ab | Compounds |
| AU2003220401A1 (en) * | 2002-03-18 | 2003-10-08 | Bristol-Myers Squibb Company | Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases |
| NZ536504A (en) * | 2002-05-24 | 2008-04-30 | Millennium Pharm Inc | CCR9 inhibitors and methods of use thereof |
| US20070021466A1 (en) * | 2002-11-18 | 2007-01-25 | Solomon Ungashe | CCR2 inhibitors and methods of use thereof |
| DE60314175T2 (de) * | 2002-11-18 | 2008-01-24 | Chemocentryx Inc., Mountain View | Arylsulfonamide |
| US20060100245A1 (en) * | 2002-12-19 | 2006-05-11 | Neurogen Corporation | Substituted biphenyl-4-carboxylic acid arylamide analogues |
| AU2003290346A1 (en) * | 2002-12-24 | 2004-07-22 | Biofocus Plc | Compound libraries of 2,3-substituted pyrazine derivatives capable of binding to g-protein coupled receptors |
| CA2526385C (en) * | 2003-05-29 | 2008-07-22 | Abbott Laboratories | Continuous dosing regimen with abt-751 |
| EP1643960A2 (en) * | 2003-07-02 | 2006-04-12 | Merck & Co., Inc. | Arylsulfonamide derivatives |
| US7622583B2 (en) * | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
| US9715915B2 (en) | 2014-10-30 | 2017-07-25 | Samsung Electronics Co., Ltd. | Magneto-resistive devices including a free layer having different magnetic properties during operations |
-
2006
- 2006-01-13 MX MX2007008474A patent/MX2007008474A/es active IP Right Grant
- 2006-01-13 ES ES11002389.2T patent/ES2440965T3/es not_active Expired - Lifetime
- 2006-01-13 PL PL06718419T patent/PL1838674T3/pl unknown
- 2006-01-13 CA CA2594726A patent/CA2594726C/en not_active Expired - Lifetime
- 2006-01-13 PL PL11002389T patent/PL2354126T3/pl unknown
- 2006-01-13 JP JP2007551428A patent/JP5253815B2/ja not_active Expired - Lifetime
- 2006-01-13 EP EP11002389.2A patent/EP2354126B1/en not_active Expired - Lifetime
- 2006-01-13 DK DK11002389.2T patent/DK2354126T3/da active
- 2006-01-13 DE DE602006020979T patent/DE602006020979D1/de not_active Expired - Lifetime
- 2006-01-13 EP EP12162572A patent/EP2474532A1/en not_active Withdrawn
- 2006-01-13 AU AU2006204750A patent/AU2006204750C1/en not_active Expired
- 2006-01-13 US US11/332,786 patent/US20060173019A1/en not_active Abandoned
- 2006-01-13 WO PCT/US2006/001341 patent/WO2006076644A2/en not_active Ceased
- 2006-01-13 DK DK06718419.2T patent/DK1838674T3/da active
- 2006-01-13 EP EP06718419A patent/EP1838674B9/en not_active Expired - Lifetime
- 2006-01-13 AT AT06718419T patent/ATE503741T1/de active
-
2007
- 2007-07-11 IL IL184539A patent/IL184539A/en active IP Right Grant